Bedel Financial Consulting, Inc. Scynexis Inc Transaction History
Bedel Financial Consulting, Inc.
- $716 Million
- Q3 2024
Shares
3 transactions
Others Institutions Holding SCYX
# of Institutions
48Shares Held
13.7MCall Options Held
21.9KPut Options Held
2.6K-
Federated Hermes, Inc. Pittsburgh, PA3.6MShares$4.46 Million0.01% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$2.77 Million0.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$2.09 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.45MShares$1.8 Million0.13% of portfolio
-
Amh Equity LTD600KShares$744,0001.24% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $40.5M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...